{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T18:40:19Z","timestamp":1792608019949,"version":"4.5.0"},"reference-count":29,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"11","content-domain":{"domain":["www.ahajournals.org"],"crossmark-restriction":true},"short-container-title":["Hypertension"],"published-print":{"date-parts":[[2026,11]]},"abstract":"<jats:sec>\n                    <jats:title>BACKGROUND:<\/jats:title>\n                    <jats:p>In 2025, the Endocrine Society (ES) updated the guidelines for primary aldosteronism (PA), introducing more inclusive diagnostic criteria: plasma renin activity (PRA) \u22641 ng\/mL per hour, plasma aldosterone concentration (PAC) \u22657.5 ng\/dL by liquid chromatography\u2013tandem mass spectrometry, and aldosterone-to-renin ratio &gt;15. We compared PA positivity by comparing these updated criteria against broader permissive criteria (PRA &lt;1 ng\/mL per hour, PAC &gt;5 ng\/dL, without an aldosterone-to-renin ratio requirement).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>METHODS:<\/jats:title>\n                    <jats:p>We retrospectively analyzed deidentified adults with PRA and PAC measurements between January and August 2025. Patients were categorized by ES versus permissive criteria. Biochemical and clinical characteristics were compared.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS:<\/jats:title>\n                    <jats:p>\n                      Of 60\u2009449 patients, 13.0% (n=7883) met ES screening criteria for PA versus 26.2% (n=15\u2009872) by permissive criteria. Among the 8006 (13.2%) permissive-positive\/ES-negative patients, 6325 did not meet ES criteria due to PAC 5 to 7.5 ng\/dL, despite 55.2% having a PRA &lt;0.5 ng\/mL per hour. An additional 1681 patients were excluded by ES criteria because the aldosterone-to-renin ratio was \u226415, despite a median PAC of 9.00 (8\u201310) ng\/dL. Among permissive-positive\/ES-negative patients, PRA \u2264 0.25 ng\/mL per hour was associated with higher odds of atrial fibrillation (odds ratio, 2.38;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      =0.004), hypertension (odds ratio, 1.27;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      =0.0002) and hypokalemia (K&lt;3.5; odds ratio, 1.66;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      =0.0012).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSIONS:<\/jats:title>\n                    <jats:p>Current ES thresholds potentially exclude PA cases with a biochemical phenotype consistent with milder or earlier renin-independent aldosterone production. If validated in cohorts with comprehensive clinical data, the biochemical definition of PA may need to expand to include a greater proportion of individuals with renin-independent aldosterone production.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1161\/hypertensionaha.126.27634","type":"journal-article","created":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T09:00:10Z","timestamp":1789635610000},"update-policy":"https:\/\/doi.org\/10.1161\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":1,"title":["Evaluation of Current Screening Thresholds for the Detection of Primary Aldosteronism"],"prefix":"10.1161","volume":"83","author":[{"given":"Kyrsten R.","family":"Voorhies","sequence":"first","affiliation":[{"name":"Quest Diagnostics, Cardiovascular, Endocrinology, Metabolism and Wellness Research, San Juan Capistrano, CA (K.R.V., C.B., M.A.A., S.B.D., M.M.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-9544-0959","authenticated-orcid":true,"given":"Caixia","family":"Bi","sequence":"additional","affiliation":[{"name":"Quest Diagnostics, Cardiovascular, Endocrinology, Metabolism and Wellness Research, San Juan Capistrano, CA (K.R.V., C.B., M.A.A., S.B.D., M.M.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0333-8632","authenticated-orcid":true,"given":"Mopelola A.","family":"Adeyemo","sequence":"additional","affiliation":[{"name":"Quest Diagnostics, Cardiovascular, Endocrinology, Metabolism and Wellness Research, San Juan Capistrano, CA (K.R.V., C.B., M.A.A., S.B.D., M.M.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjay B.","family":"Dixit","sequence":"additional","affiliation":[{"name":"Quest Diagnostics, Cardiovascular, Endocrinology, Metabolism and Wellness Research, San Juan Capistrano, CA (K.R.V., C.B., M.A.A., S.B.D., M.M.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0314-9252","authenticated-orcid":true,"given":"Anand","family":"Vaidya","sequence":"additional","affiliation":[{"name":"Division of Endocrinology, Diabetes, and Metabolism, Center for Adrenal Disorders, Mass General Brigham and Harvard Medical School, Boston (A.V.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4399-5733","authenticated-orcid":true,"given":"Michael J.","family":"McPhaul","sequence":"additional","affiliation":[{"name":"Division of Endocrinology, University of Texas Southwestern Medical School, Dallas (M.J.M.P.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-2154-0176","authenticated-orcid":true,"given":"Marco","family":"Marcelli","sequence":"additional","affiliation":[{"name":"Quest Diagnostics, Cardiovascular, Endocrinology, Metabolism and Wellness Research, San Juan Capistrano, CA (K.R.V., C.B., M.A.A., S.B.D., M.M.)."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgaf284"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2015-4061"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamasurg.2021.0254"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.7326\/M20-4873"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.121.18118"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.7326\/M20-0065"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgab348"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgaa606"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1210\/er.2018-00139"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.125.24648"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgaf663"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.124.22884"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1093\/ajh\/hpad032"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1373\/clinchem.2010.146449"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1373\/clinchem.2015.251009"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamacardio.2018.2003"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.119.14063"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41371-020-00395-2"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.124.073507"},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.123.066389"},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.0000001039"},{"key":"e_1_3_3_23_2","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.116.08952"},{"key":"e_1_3_3_24_2","doi-asserted-by":"publisher","DOI":"10.1097\/hjh.0000000000000775"},{"key":"e_1_3_3_25_2","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.684111"},{"key":"e_1_3_3_26_2","doi-asserted-by":"publisher","DOI":"10.1161\/HYP.0000000000000264"},{"key":"e_1_3_3_27_2","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.124.23385"},{"key":"e_1_3_3_28_2","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.121.023082"},{"key":"e_1_3_3_29_2","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.122.19377"},{"key":"e_1_3_3_30_2","doi-asserted-by":"publisher","DOI":"10.1093\/ajh\/hpaf163"}],"container-title":["Hypertension"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ahajournals.org\/doi\/full\/10.1161\/HYPERTENSIONAHA.126.27634","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T18:00:32Z","timestamp":1792605632000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ahajournals.org\/doi\/10.1161\/HYPERTENSIONAHA.126.27634"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":29,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["10.1161\/HYPERTENSIONAHA.126.27634"],"URL":"https:\/\/doi.org\/10.1161\/hypertensionaha.126.27634","relation":{},"ISSN":["0194-911X","1524-4563"],"issn-type":[{"value":"0194-911X","type":"print"},{"value":"1524-4563","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"2026-07-05","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-08-31","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-09-17","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}